Market Spotlight: Systemic Hypertension
|出版日期||內容資訊||英文 58 Pages
|焦點市場分析:全身動脈性高血壓 Market Spotlight: Systemic Hypertension|
|出版日期: 2020年08月14日||內容資訊: 英文 58 Pages||
據估計，2017年全球全身動脈性高血壓的的患病率約為17億，預計到2026年將增至19億。就性別來看，男性略多一些，2017年25歲以上的患病人數中估計有53.31％是男性。批准藥物的靶點五花八門，給藥途徑主要是口服，還有少量靜脈內，肌肉內和透皮製劑。臨床開發中的大多數藥物都處於II期，其中一種藥物處於NDA / BLA期。在區域臨床試驗方面，美國大幅度領先世界，歐盟則是德國，亞洲為韓國。
This Market Spotlight report covers the Systemic Hypertension market, comprising key marketed and pipeline drugs, clinical trials, key upcoming and regulatory events, probability of success, patent information, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
Datamonitor Healthcare estimates that in 2017, there were approximately 1.7 billion prevalent cases of systemic hypertension worldwide, and forecasts that number to increase to 1.9 billion prevalent cases by 2026.
Systemic hypertension has a slight male predominance. Globally, Datamonitor Healthcare estimates that in 2017, 53.31% of cases aged 25 years and over were male.
The approved drugs in the systemic hypertension space focus on a wide variety of targets. These drugs are commonly administered via the oral route, with a few products being available in intravenous, intramuscular, and transdermal formulations.
The largest proportion of industry-sponsored drugs in active clinical development for systemic hypertension are in Phase III, with only one drug in the NDA/BLA phase.
Therapies in development for systemic hypertension focus on a wide variety of targets. The majority of pipeline drugs are administered via the oral route, with the remainder being intranasal, subcutaneous, and topical formulations.
The only high-impact upcoming event in the systemic hypertension space is topline Phase III trial results for firibastat. The overall likelihood of approval of a Phase I systemic hypertension asset is 5.4%, and the average probability a drug advances from Phase III is 65.2%. Drugs, on average, take 6.4 years from Phase I to approval, compared to 10.0 years in the overall cardiovascular space.
The distribution of clinical trials across Phase I-IV indicates that the majority of trials for hypertension have been in the late phases of development, with 51% of trials in Phase III-IV, and 49% in Phase I-II.
The US has a substantial lead in the number of hypertension clinical trials globally. Germany leads the major European markets, while South Korea has the top spot in Asia.
Clinical trial activity in the hypertension space is dominated by completed trials. Novartis has the highest number of completed clinical trials for hypertension, with 429 trials. Novartis also leads industry sponsors with by far the highest overall number of clinical trials for hypertension.